Clinical Trial Simulations
Jul 07, 2017
Modeling & Simulation Webinar
Clinical Trial Simulations: An Efficient Tool for Improved Study Designs, Dose Selection and Go/No-go Investment Decisions, by Per Olsson and Alberto Russu.
Europe: Tuesday 19/09 at 3pm CEST.
US: Thursday 28/09 at 9am CDT.
Feb 04, 2018
In silico evaluation of pharmacokinetic optimization for antimitogram-based clinical trials
Through collaboration with the university of Lyon, Simulo was intensively used to simulate and optimize antimitogram-based clinical trials. The result is an impressive simulation-based paper published in the journal for American Association for Cancer Research.
Jan 12, 2018
Two-day Clinical Trial Simulation course at PAGE 2018
In the context of the next PAGE meeting, SGS Exprimo is running a two-day Clinical Trial Simulation course on Monday and Tuesday 28-29 May.
Nov 20, 2017
Clinical Trial Simulation course at University of Lyon
Ruben Faelens from SGS Exprimo teached a 4-hour session at the Master Pharmacology, Modeling and Clinical trials (PHAME) at the University Claude Bernard Lyon 1, using Simulo!
Sep 28, 2017
SGS Exprimo delegation at ACoP 2017
SGS Exprimo will be present at the American Conference on Pharmacometrics, 15-18 October in Fort Lauderdale. Come visit our booth to learn more about our consulting services. We will also demonstrate the Simulo software for clinical trial and dosing simulations.
Sep 22, 2017
Public Clinical Trial Simulation course in collaboration with Freie Universität Berlin
SGS Exprimo is running a public two-day Clinical Trial Simulation course on Thursday and Friday 2-3 November in Germany, together with Professor Charlotte Kloft’s team at Freie Universität Berlin.
Jun 05, 2017
Two-day Clinical Trial Simulation course at PAGE 2017
In the context of the PAGE meeting, SGS Exprimo ran a two-day satellite course on Monday and Tuesday 5-6 June.
Apr 04, 2017
Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy
Baseline disease severity was the most important predictor of seizure probability. Simulations suggest that an initial target dose >200 mg/day could potentially benefit patients with greater disease severity.
Mar 01, 2017
How can modelling and simulation optimize the clinical development of biosimilars?
Bernardo de Miguel Lillo explores the competitive advantages SGS Exprimo can offer in the development of biosimilars
Feb 23, 2017
Simulo Press Release
SGS Exprimo officially launches Simulo platform to provide modeling and simulation solutions for clinical trial design optimization.